We are currently studying the role of chemotherapy with the addition of Erbitux, a novel agent that targets gastric cancer cell receptors, given prior to surgery and then after surgery in association with radiation therapy.

For information about this trial and others that are are actively accruing patients, you can search our online database or call the clinical trials office at 212.263.6485.

Others areas of active translational research in gastric cancer relating to understanding Helicobacter Pylori, and its role in causing gastric cancer, and strategies to better screen and improve outcome in high risk patients are ongoing.

For further information on these areas or any other questions relating to gastroesophageal junction and gastric cancer research programs and trials, please contact Kajal Desai at 212.263.6381 in the Department of Surgery.